Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

Mounjaro explained as 'All About That Bass' singer Meghan Trainor admits to using it amid major weight loss transformation.

Singer Meghan Trainor is opening up about the weight loss drug she took to lose weight, but it might not be a good idea. The ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...